MARKET

INMB

INMB

Inmune Bio Inc
NASDAQ
1.419
+0.139
+10.85%
Opening 14:29 03/11 EDT
OPEN
1.380
PREV CLOSE
1.280
HIGH
1.470
LOW
1.350
VOLUME
800.91K
TURNOVER
--
52 WEEK HIGH
11.64
52 WEEK LOW
1.160
MARKET CAP
37.72M
P/E (TTM)
-0.6629
1D
5D
1M
3M
1Y
5Y
1D
INmune Bio Raised to Buy From Neutral by LUCID CAPITAL MARKETS
Dow Jones · 6h ago
INmune Bio Price Target Raised to $9.00/Share From $2.00 by LUCID CAPITAL MARKETS
Dow Jones · 6h ago
LUCID CAPITAL MARKETS Upgrades INmune Bio to Buy, Raises Price Target to $9
Benzinga · 6h ago
INmune Bio upgraded to Buy from Neutral at Lucid Capital
TipRanks · 8h ago
Weekly Report: what happened at INMB last week (0302-0306)?
Weekly Report · 2d ago
Weekly Report: what happened at INMB last week (0223-0227)?
Weekly Report · 03/02 09:52
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
TipRanks · 02/27 16:34
INmune Bio Highlights CORDStrom RDEB Program and IP Strength
TipRanks · 02/27 15:21
More
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Webull offers INmune Bio Inc stock information, including NASDAQ: INMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INMB stock methods without spending real money on the virtual paper trading platform.